KPTI · Karyopharm Therapeutics Inc.
AI read · Bad for KPTI
The AI's read
Karyopharm reported Q2 revenue of $33.4M, down from $37.9M, and said liquidity only runs to September 2026 while discussing an sNDA for selinexor in myelofibrosis. They reaffirmed 2026 revenue guidance of $130–150M but flagged debt and lender discussions. The market hit KPTI about -7% on the print and RSI is 74.74, so sellers moved quickly after the update. That price action implies cash and debt fears outweigh the clinical story for now. We lean bearish because runway and upcoming debt create real near-term downside risk despite the clinical upside. If they secure financing or clear regulatory hurdles, the narrative can reverse fast.